Doxorubicin Activates Ryanodine Receptors in Rat Lymphatic Muscle Cells to Attenuate Rhythmic Contractions and Lymph Flow

Doxorubicin is a risk factor for secondary lymphedema in cancer patients exposed to surgery or radiation. The risk is presumed to relate to its cytotoxicity. However, the present study provides initial evidence that doxorubicin directly inhibits lymph flow and this action appears distinct from its c...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Pharmacol Exp Ther
Main Authors: Stolarz, Amanda J., Sarimollaoglu, Mustafa, Marecki, John C., Fletcher, Terry W., Galanzha, Ekaterina I., Rhee, Sung W., Zharov, Vladimir P., Klimberg, V. Suzanne, Rusch, Nancy J.
Formato: Artigo
Idioma:Inglês
Publicado: The American Society for Pharmacology and Experimental Therapeutics 2019
Assuntos:
Cardiovascular
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6815939/
https://ncbi.nlm.nih.gov/pubmed/31439806
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.119.257592
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares